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Dear Editor,
The article “efficacy of hepatitis B vaccine in those who 
lost hepatitis B surface antigen during follow-up” pub-
lished recently in Hepatitis Monthly (1), described the ef-
ficacy of HBV vaccine in chronic HBV patients who had 
been found negative for HBsAg and HBV DNA in sera. The 
manuscript was highlighted by an Editorial in the same 
issue (2). The manuscript dealt with a group of chronic 
HBV patients who were described as having occult HBV 
(3), with one major difference; usually occult HCV is de-
fined as the presence of low levels of HBV viremia in the 
absence of detectable HBsAg but detectable anti-HBcAb, 
whereas in this manuscript (1) the authors considered 
patients with undetectable HBsAg (with prior positive 
HBsAg) as well as undetectable HBV DNA levels (< 50 cop-
ies/mL of HBV DNA) with anti-HBe and anti-HBc antibod-
ies. Thirty-four such patients and 52 control healthy indi-
viduals were vaccinated with three doses of HBV vaccine 
(Engerix-B,  SmithKline  Beecham);  the  antibody  levels 
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were determined one month after the last dose of vac-
cination. In the control group, 87% of individuals devel-
oped protective levels of anti-HBs antibodies as has been 
reported earlier (4). The major finding of the manuscript 
was that in 24% of the selected occult HBV patients, pro-
tective levels of anti-HBs antibodies developed. However, 
the anti-HBs antibody levels were significantly lower than 
those of the healthy individuals (mean ± SD: 68 ± 32.66 vs. 
344.6 ± 38.99, p < 0.001). The authors suggested that “the 
development of anti-HBs antibody may be a clue showing 
that they have protection and are less likely prone to de-
velop chronic hepatitis, cirrhosis and hepatocellular car-
cinoma”. This is an interesting study as it deals with HBV 
in patients whose disease outcome is not very clear. Also 
the study suggests that the role of HBV vaccine could be 
extended from prevention to therapeutic in certain cases 
of chronic HBV. However, the sole appearance of anti-HBs 
antibodies cannot be taken to reflect viral clearance or 
non-progression to liver diseases. It has been shown re-
cently that seroconversion from HBsAg positive to anti-
HBs antibodies positive does not necessarily correlate to 
viral clearance (5). In this respect, it is important to note 
that perhaps in patients with occult HBV and undetect-
able serum HBsAg, there may be no or reduced tolerance 
against HBsAg as compared to those with active chronic   Copyright  c 2011, BRCGL, Published by Kowsar M.P.Co.  All rights reserved.Hepat Mon. 2011;11(6):477-478
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HBV with high serum levels of HBsAg and therefore, the 
current HBV vaccine may be more effective in inducing 
anti-HBs antibodies. However, despite the presence of an-
ti-HBs antibodies, low levels of viral replication may con-
tinue in the hepatocytes leading to further liver diseases 
such as cirrhosis, fibrosis and hepatocellular carcinoma. 
It is imperative that the patients with positive response 
to HBV vaccine in the current study (1), be followed for 
a longer duration to clearly examine the role of the in-
duced anti-HBs antibodies in viral clearance or therapy 
of occult chronic HBV. As acknowledged by the authors 
(1), liver biopsies could have provided more information 
regarding viral clearance in response to the induction 
of anti-HBs antibodies. In addition, the study needs to 
be expanded to a larger number of patients to make im-
portant conclusions. Nevertheless, the paper represents 
an important study in examining the role of the current 
HBV vaccine in inducing protective anti-HBs antibodies 
in patients with occult HBV and may prove to be useful in 
expanding the role of the current HBV vaccine in therapy 
of occult chronic HBV.
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